Spectral AI posts investor presentation: $250M+ gov funding, UKCA approval, FDA De Novo in wound-care AI

Spectral AI, Inc.

Posted updated investor presentation Sept 14, 2026 highlighting DeepView AI+multispectral imaging platform for wound care.
Cites 13-year milestone track record backed by $250M+ in non-dilutive government funding from 2013-2026.
Regulatory progress includes UKCA approval and FDA De Novo pathway; DeepView supports multiple indications.
DeepView predicts wound healing in seconds during initial patient visit; company prioritizing profitable markets for near-term commercialization.
Extensive patent portfolio, trade secrets and truthed images cited as competitive barriers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.